Log In
BCIQ
Print this Print this
 

Sirturo, bedaquiline (TMC207) (formerly R207910)

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionDiarylquinoline (DARQ) antibiotic
Molecular Target Mycobacterial F1F0-ATP synthase
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationTuberculosis
Indication DetailsTreat multidrug-resistant tuberculosis (MDR-TB); Treat pulmonary multidrug-resistant tuberculosis (TB) infection
Regulatory Designation U.S. - Accelerated Approval (Treat multidrug-resistant tuberculosis (MDR-TB));
EU - Conditional Approval (Treat multidrug-resistant tuberculosis (MDR-TB));
EU - Orphan Drug (Treat multidrug-resistant tuberculosis (MDR-TB))
PartnerGlobal Alliance for TB Drug Development;
Pharmstandard OJSC

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/22/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today